Manufacturing and Service Operations Management
Vol. 22, Issue 5, Pages 1066-1087
Organ-transplanted patients typically receive high amounts of immunosuppressive drugs (e.g., tacrolimus) as a mechanism to reduce their risk of organ rejection. However, because of the diabetogenic effect of these drugs, this practice exposes them to a greater risk of new-onset diabetes after transplantation (NODAT), and hence, becoming insulin dependent. We study and develop effective medication management strategies to address the common conundrum of balancing the risk of organ rejection versus that of NODAT.
Boloori, Alireza, Soroush Saghafian, Harini A. Chakkera, and Curtiss B. Cook. "Data-Driven Management of Post-Transplant Medications: An Ambiguous Partially Observable Markov Decision Process Approach." Manufacturing and Service Operations Management 22.5 (October 2020): 1066-1087.